On Jun 29, 2018 Krystal Biotech (KRYS) with $35 Target Analyzed by Chardan Capital.

June 29, 2018 - By Lena Young

What Price Target Has Chardan Capital Given Krystal Biotech (KRYS)

With Buy rating that would indicate 136.65 % upside potential on Krystal Biotech (KRYS), Chardan Capital has started coverage of KRYS’s shares on Thursday, 28 June.

KRYS is reaching $14.79 during the last trading session, after increased 2.57%.Currently Krystal Biotech, Inc. is after 0.00% change in last June 29, 2017. KRYS has 5,264 shares volume. KRYS underperformed by 12.57% the S&P500.

Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States.The company has $152.48 million market cap. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.Currently it has negative earnings. It also engages in developing KB105, which is in preclinical studies to treat Lamellar Ichthyosis, which is an autosomal recessive disorder.

Another two news for Krystal Biotech, Inc. (NASDAQ:KRYS) were briefly brought out by: Streetinsider.com on June 28, 2018 with title “Chardan Capital Markets Starts Krystal Biotech (KRYS) at Buy”. The other Benzinga.com‘s article was titled “40 Biggest Movers From Yesterday” and brought out on June 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.